MEDS · DataMeds AI, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 17, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-22 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Exercise↑
Filing footnotes — Common Stock (Direct)
Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person. Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants. |
Common Stock
|
100,000 |
| 2026-06-22 | Patel Prashant |
Director, CEO |
Exercise↑
Filing footnotes — Common Stock (Direct)
Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person. |
Common Stock
|
100,000 |
| 2026-06-22 | Patel Prashant |
Director, CEO |
Exercise↑
Filing footnotes — Warrant (Direct)
Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants. |
Warrant
|
100,000 |
| 2026-06-22 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Exercise↑
|
Warrant
|
100,000 |
| 2026-03-31 | Patel Prashant |
Director, CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. |
Common Stock
|
5,000,000 |
| 2026-03-31 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. |
Common Stock
|
5,000,000 |
| 2026-03-31 | Patel Prashant |
Director, CEO |
Award↑
Filing footnotes — Warrant (Direct)
The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. |
Warrant
|
5,000,000 |
| 2026-03-31 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Warrant (Direct)
The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. |
Warrant
|
5,000,000 |
| 2025-07-02 | PETERSON MICHAEL L |
Director, Chief Executive Officer |
Award↓
Filing footnotes — Common Stock (Direct)
The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on July 2, 2026, and 67,000 shares vesting on July 2, 2027. |
Common Stock
|
200,000 |
| 2025-03-21 | ANDERSON DONALD WILLIAM |
Director |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on March 4, 2026, and 67,000 shares vesting on March 4, 2027. |
Common Stock, Par Value $0.0001
|
200,000 |
| 2025-03-21 | Syed Sajid |
Director |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on March 4, 2026, and 67,000 shares vesting on March 4, 2027. |
Common Stock, Par Value $0.0001
|
200,000 |
| 2025-03-21 | Norton Brian |
Chief Executive Officer |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely upon the achievement of certain financial metrics for the years ending December 31, 2025, 2026, and 2027. The first vesting opportunity is during the first quarter of 2026. |
Common Stock, Par Value $0.0001
|
9,000,000 |
| 2025-03-21 | Patel Prashant |
Director, CEO |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. |
Common Stock, Par Value $0.0001
|
1,882,247 |
| 2025-03-21 | Panchal Nikul |
Chief Pharmacy Officer |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Indirect)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely on the basis of the passage of time, with 50% vesting immediately and the remaining 50% vesting on October 1, 2025. |
Common Stock, Par Value $0.0001
(I)
|
90,000 |
| 2025-03-21 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Indirect)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. |
Common Stock, Par Value $0.0001
(I)
|
600,000 |
| 2025-03-21 | SHANAHAN REBECCA M |
Director |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on March 4, 2026, and 67,000 shares vesting on March 4, 2027. |
Common Stock, Par Value $0.0001
|
200,000 |
| 2025-03-21 | Patel Prashant |
Director, CEO |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Indirect)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. |
Common Stock, Par Value $0.0001
(I)
|
1,500,000 |
| 2025-03-21 | Patel Prashant |
Director, CEO |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Indirect)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. |
Common Stock, Par Value $0.0001
(I)
|
700,000 |
| 2025-03-21 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. |
Common Stock, Par Value $0.0001
|
2,882,247 |
| 2025-03-21 | AJJARAPU SURENDRA K |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Indirect)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. |
Common Stock, Par Value $0.0001
(I)
|
600,000 |
| 2025-03-21 | Pirani Shafaat |
Chief Clinical Officer |
Award↑
Filing footnotes — Common Stock, Par Value $0.0001 (Direct)
Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely on the basis of the passage of time, with 15,000 shares vesting immediately, 10,000 shares vesting on October 1, 2026, and 10,000 shares vesting on October 1, 2027. |
Common Stock, Par Value $0.0001
|
35,000 |